Biostax Corp (BTAX)

Biostax Corp. is a healthcare company focused on biotechnology and biopharmaceutical development. The company works to acquire, develop, and commercialize pharmaceutical and biotechnology products, with programs spanning several therapeutic and technology areas. Its lead investigational candidate is Lodonal, a once-daily immune system regulator being developed for the management of HIV/AIDS. Biostax also references a Global Telehealth platform, a Medtech asset in early development that applies blockchain and smart contracts to prescription and electronic health record security, and JKB-122, an investigational long-acting TLR4 antagonist studied for autoimmune hepatitis, NAFLD, and NASH. Additional work includes Low Dose Naltrexone and programs related to hyperphosphatemia. The company has a licensing agreement with Cytocom Inc. Formerly known as Immune Therapeutics, Inc., it adopted the Biostax Corp. name in October 2023 and is headquartered in Winter Park, Florida. The listed security is common stock on OTC Markets.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.